Eton Pharmaceuticals (NASDAQ:ETON) Coverage Initiated at Craig Hallum

Equities research analysts at Craig Hallum began coverage on shares of Eton Pharmaceuticals (NASDAQ:ETON) in a research note issued to investors on Monday, Briefing.com reports. The firm set a “buy” rating and a $8.00 price target on the stock. Craig Hallum’s target price would indicate a potential upside of 115.63% from the stock’s previous close.

Eton Pharmaceuticals Trading Down 1.1 %

ETON opened at $3.71 on Monday. The firm has a market cap of $95.31 million, a price-to-earnings ratio of -123.67 and a beta of 1.19. Eton Pharmaceuticals has a 12-month low of $2.42 and a 12-month high of $5.81. The stock’s 50-day moving average price is $3.78 and its 200 day moving average price is $4.07.

Eton Pharmaceuticals (NASDAQ:ETON) last released its quarterly earnings data on Thursday, March 14th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.05). The business had revenue of $7.31 million during the quarter, compared to analysts’ expectations of $7.70 million. Eton Pharmaceuticals had a negative net margin of 2.96% and a negative return on equity of 6.21%.

Hedge Funds Weigh In On Eton Pharmaceuticals

A number of large investors have recently bought and sold shares of the company. Westside Investment Management Inc. increased its position in shares of Eton Pharmaceuticals by 6.6% in the fourth quarter. Westside Investment Management Inc. now owns 563,110 shares of the company’s stock valued at $2,466,000 after buying an additional 34,800 shares in the last quarter. EAM Investors LLC purchased a new stake in Eton Pharmaceuticals in the 3rd quarter worth approximately $1,070,000. Acuitas Investments LLC grew its holdings in shares of Eton Pharmaceuticals by 124.7% during the 4th quarter. Acuitas Investments LLC now owns 492,054 shares of the company’s stock worth $2,155,000 after purchasing an additional 273,054 shares during the period. Bailard Inc. acquired a new stake in Eton Pharmaceuticals during the 4th quarter worth approximately $99,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in Eton Pharmaceuticals during the third quarter valued at approximately $160,000. Hedge funds and other institutional investors own 27.86% of the company’s stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.